Clinical Trial Update: Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action [NA]

View source ↗

Summary

A completed clinical trial evaluated dapagliflozin for effects on mitochondrial dysfunction and impaired insulin signaling, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Mitochondrial Dysfunctions Syndrome

Drugs mentioned

• Forxiga (dapagliflozin) (dapagliflozin)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Insulin Sensitivity, Multiple Mitochondrial Dysfunctions Syndrome | NA | Status: COMPLETED | Results posted: 2019-10-29